Nonlinear dorzolamide pharmacokinetics in rats: Concentration-dependent erythrocyte distribution and drug-metabolite displacement interaction

Drug Metabolism and Disposition

Volumn 24, Issue 6, 1996, Pages 659-663

  Wong, Bradley K ^a   Bruhin, Patrick J ^a   Barrish, Andrea ^a   Lin, Jiunn H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEETHYLDORZOLAMIDE; DORZOLAMIDE; DRUG METABOLITE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; AREA UNDER THE CURVE; ARTICLE; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; ERYTHROCYTE; INTRAVENOUS DRUG ADMINISTRATION; MALE; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RAT;

ADMINISTRATION, ORAL; ANALYSIS OF VARIANCE; ANIMALS; CARBONIC ANHYDRASE INHIBITORS; ERYTHROCYTES; INJECTIONS, INTRAVENOUS; MALE; RATS; RATS, SPRAGUE-DAWLEY; SULFONAMIDES; THIOPHENES;

ANIMALIA;

EID: 0030047462     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. R.-F. Wang, J. B. Serle, S. M. Podos, and M. F. Sugrue: The ocular hypotensive effect of the topical carbonic anhydrase inhibitor, L-671,152, in glaucomatous monkeys. Arch. Ophthalmology 108, 511-513 (1990).
2. M. Wilkerson, M. Cyrlin, E. A. Lippa, D. Esposito, D. Deasy, D. Panebianco, R. Fazio, M. Yablonski, and M. B. Shields: Four-week safety and efficacy study of dorzolamide, a novel, active topical carbonic anhydrase inhibitor. Arch. Ophthalmol. 111, 1343-1350 (1993).
3. T. Hasegawa, K. Hara, T. Kenmochi, and S. Hata: In vitro metabolism of dorzolamide, a novel potent carbonic anhydrase inhibitor, in rat liver microsomes. Drug Metab. Dispos. 22, 916-921 (1994).
4. T. Hasegawa, K. Hara, and S. Hata: Binding of dorzolamide and its metabolite, N- deethylated dorzolamide to human erythrocytes in vitro. Drug. Metab. Dispos. 22, 377-382 (1994).
5. J. Connor, T. Keilani, R. Segal, G. Winchell, W. Tanaka, R. Swithenbank, B. Levine, and D. Batlle: Pharmacokinetics and safety of dorzolamide (MK-507) in patients with moderate renal impairment. Invest. Ophthalmol. Vis. Sci. 36, S738 (1995).
6. B. K. Wong, P. J. Bruhin, M. Chiba, R. Wang, and J. H. Lin: Metabolism of dorzolamide by human liver microsomes and liver slices. ISSX Proc. 8, 140 (1995).
7. J. H. Lin, E. H. Ulm, and L. E. Los: Dose-dependent stereopharmacokinetics of 5,6-dihydro-4H-(4(isobutylamino)thieno(2,3-B) thiopyran-2-sulfonamide-7,7-dioxide, a potent carbonic anhydrase inhibitor, in rats. Drug Metab. Dispos. 19, 233-238 (1991).
8. J. H. Lin, I.-W. Chen, E. H. Ulm, J. R. Gehret, and D. E. Duggan: Dose-dependent pharmacokinetics of MK-417, a potent carbonic anhydrase inhibitor, in rabbits following single and multiple doses. Drug Metab. Dispos. 18, 836-841 (1990).
9. T. H. Maren: Carbonic anhydrase: Chemistry, physiology, and inhibition. Physiol. Rev. 47, 595-781 (1967).
10. P. J. McNamara, K. Stoeckel, and W. H. Ziegler: Pharmacokinetics of ceftriaxone following intravenous administration of a 3 g dose. Eur. J. Clin. Pharmacol. 22, 71-75 (1982).
11. J. Q. Rose, A. M. Yurchak, and W. J. Jusko: Dose-dependent pharmacokinetics of prednisone and prednisolone in man. J. Pharmacokinet. Biopharmacol. 9, 389-417 (1981).
12. J. R. Weeks and J. D. Davis: Chronic intravenous cannulas for rat. J. Appl. Physioi. 10, 540-542 (1964).
13. K. S. Pang and K. C. Kwan: A commentary: Methods and assumptions in the kinetic estimation of metabolite formation. Drug Metab. Dispos. 11, 79-84 (1979).
14. B. K. Matuszewski, M. L. Constanzer, E. J. Woolf, T. Au, and H. Haddix: Determination of MK-507, a novel topically active carbonic anhydrase inhibitor, and its de-ethylated metabolite in human whole blood, plasma, and urine by high-performance liquid chromatography. J. Chromatogr. B 653, 77-85 (1994).
15. B. K. Wong, T. F. Woolf, T. Chang, and L. R. Whitfield: Metabolic disposition of trimetrexate, a nonclassical dihydrofolate reductase inhibitor, in rat and dog. Drug Metab. Dispos. 18, 980-986 (1990).
16. B. K. Wong, P. J. Bruhin, and J. H. Lin: Dose-dependent pharmacokinetics of L-693,612, a carbonic anhydrase inhibitor, following oral administration in rats. Pharmaceut. Res. 11, 438-441 (1994).
17. J. H. Zar: "Biostatistical Analysis," 2nd ed. Prentice-Hall, Englewood Cliffs, N.J., 1984.
18. G. Lonnerholm, P. J. Wistrand, and E. Barany: Carbonic anhydrase isozymes in the rat kidney. Effect of chronic acetazolamide treatment. Ada Physiol. Scand. 126, 51-60 (1986).
19. F. C. Lam, C. T. Hung, and D. G. Perrier: Estimation of variance for harmonic mean. J. Pharmacol. Sci. 74, 229-231 (1985).